Anti-dengue virus antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9499607-B2
Application number	US-201313951066-A
Country	US
Kind code	B2
Filing date	Jul 25, 2013
Priority date	Aug 7, 2012
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

First claim

What is claimed is:

1. An antibody agent specific to Dengue virus,
which antibody agent comprises a heavy chain variable region and a light chain variable region, each of which includes complementarity determining regions (CDRs), wherein
the heavy chain variable region comprises CDRs whose amino acid sequences are set forth in SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25; and
the light chain variable region comprises CDRs whose amino acid sequences are set forth in SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

2. The antibody agent according to claim 1 , which is an IgG.

3. The antibody agent according to claim 1 , which is a monoclonal antibody.

4. The antibody agent according to claim 1 , wherein the antibody agent is selected from the group consisting of: a mouse antibody, a humanized antibody, a human antibody, a purified antibody, an isolated antibody, a chimeric antibody, a polyclonal antibody, and combinations thereof.

5. The antibody agent according to claim 1 , wherein the antibody agent is selected from the group consisting of: a Fab fragment, a Fab′ fragment, a F(ab′) 2 fragment, a Fd fragment, a Fd′ fragment, a Fv fragment, a dAb fragment, a scFv fragment, an isolated CDR region, a dsFv diabody, a single chain antibody, and combinations thereof.

6. A kit comprising:
at least one antibody agent according to claim 1 ;

a syringe, needle, or applicator for administration of the at least one antibody or fragment thereof that is specific to Dengue virus to a subject; and instructions for use.

7. A method of manufacturing a pharmaceutical composition, the method comprising steps of:
providing an antibody agent according to claim 1 ; and
formulating the antibody agent with at least one pharmaceutically acceptable carrier or excipient,

so that a pharmaceutical composition is generated.

8. An antibody agent whose heavy chain is or comprises an amino acid sequence as set forth in SEQ ID NO: 21 or whose light chain is or comprises an amino acid sequence as set forth in SEQ ID NO: 22 or both.

9. A composition comprising an immunoglobulin heavy chain of SEQ ID NO: 21.

10. A composition comprising an immunoglobulin light chain of SEQ ID NO: 22.

Assignees

• Massachusetts Inst Technology

Inventors

• Sasisekharan Ram
• Robinson Luke Nathaniel
• Tharakaraman Kannan

Classifications

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• G01N2469/10

  Detection of antigens from microorganism in sample from host · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title